Literature DB >> 10758787

Recurrent pregnancy loss associated with endometrial hyperechoic areas (endometrial calcifications): a case report and review of the literature.

V Feyles1, T N Moyana, R A Pierson.   

Abstract

Endometrial calcifications occur sporadically and are associated with infertility. Previous uterine trauma during instrumentation and/or uterine infection are likely involved in their pathogenesis. The association between endometrial calcifications and recurrent pregnancy loss has been very infrequently reported. A 28-year-old woman with a history of two consecutive first trimester pregnancy losses presented with ultrasonographic hyperechoic endometrial areas associated with histologic endometrial calcification foci. A third pregnancy conceived before starting micronized oral progesterone supplementation also spontaneously aborted at eight weeks. During the fourth pregnancy, progesterone supplementation was taken for the initial 12 weeks. The endometrial lesions were no longer detectable and the pregnancy progressed to term without complications. Endometrial calcifications, related to intrauterine bone tissue, have been previously treated with curettage or with endoscopic surgery, and to the best of our knowledge, have not been reported to disappear spontaneously. In this case, regression of the endometrial calcifications and a favorable pregnancy outcome occurred in concert with oral micronized progesterone supplementation. A combination of transvaginal ultrasonography and endometrial biopsy appears to be an effective method for diagnosing and monitoring of this rare condition.

Entities:  

Mesh:

Year:  2000        PMID: 10758787

Source DB:  PubMed          Journal:  Clin Exp Obstet Gynecol        ISSN: 0390-6663            Impact factor:   0.146


  1 in total

1.  Mineralized deposits in the uterus of a pig without pregnancy loss.

Authors:  Geon A Kim; Jun-Xue Jin; Anukul Taweechaipaisankul; Sanghoon Lee; Byung Il Yoon; Jongki Cho; Byeong Chun Lee
Journal:  J Vet Sci       Date:  2017-12-31       Impact factor: 1.672

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.